Neuropeptide Y (NPY) is a 36 amino acid peptide, which was originally isolated from the porcine brain (Tatemoto 1982) . Human NPY was isolated from acid extracts of adrenal-medullary pheochromocytoma tissue (Corder et al., 1984) . In human NPY, methionine is found at position 17 instead of leucine.
A high concentration of NPY in plasma and tumor tissue extracts of pheochromocytoma and ganglioneuroblastoma has been reported (Adrian et al., 1983; Corder et al., 1984 and Lundberg et al., 1986; Allen et al., 1987; Takahashi et al., 1987) . Corder et al.(1986) reported that about half the pheochromocytoma cases had increased plasma and tumor tissue NPY, and the other half had a low concentration. And a high concentration of IR-NPY in the conditioned medium of rat and human cultured pheochromocytoma cells was reported (Allen et al., 1984; Tischler et al., 1985) . The sequence of the cDNA encoding NPY in one pheochromocytoma was also determined (Minth et al., 1984) . From these reports, NPY is thought to be produced in these tumors and released into the systemic circulation. But there is no report concerning plasma NPY in the drainage vein of a pheochromocytoma.
To further clarify the release of NPY from a pheochromocytoma, we studied the plasma and tumor tissue immunoreactive (IR) NPY in 13 cases of pheochromocytoma and measured the IR-NPY concentration in plasma samples obtained from the jugular vein, superior vena cava, renal vein, adredal vein and inferior vena cava in 2 pheochromocytoma patients. by means of a catheter inserted into the femoral vein.
In both cases, a tumor existed in th e adrenal gland, which was confirmed at surgery. Therefore the right adrenal vein was a drainage vein of the tumor. As controls, plasma samples were also obtained from similar positions in veins in 2 patients with Cushing's disease (ACTH secreting pituitary adenoma). The plasma cortisol concentration was measured by radioimmunoassay in these plasma samples and a higher cortisol concentration in plasma from the adrenal vein was confirmed (data not shown). and extracted, as previously described (Mouri et al., 1989) . Tissue extracts were reconstituted in assay buffer (0.1M phosphate buffer, pH 7.4, containing 0.1% human serum albumin, 0.2% Triton X-100 and 0.1% sodium azide) and assayed. Sephadex G-50 column chromatography showed that most of the NPY immunoreactivity (>90%) in tumor tissue extracts of pheochromocytomas was eluted in an identical position with synthetic human NPY, while a small amount of NPY immunoreactivity was eluted in a higher molecular weight region (Fig. 3) . Sephadex G-50 column chromatography of NPY immunoreactivity in pooled plasma of pheochromocytoma patients also showed a similar elution pattern to that of a tumor extract (data not shown).
Reverse phase HPLC showed that most of the NPY immunoreactivity (>90%) in tumor tissue extracts of pheochromocytomas was eluted in an identical position with synthetic human NPY, while a small amount of NPY immunoreactivity was eluted in a similar position to synthetic human NPY with oxidated methionine (Fig. 4) . Most of the NPY immunoreactivity in plasma extracts was also eluted in an identical position with synthetic human NPY (data not shown). Corder et al.,(1986) reported that patients with pheochromocytoma could be divided into 2 subtypes according to the plasma and tissue NPY concentrations; NPY secreting and NPY non-secreting subtypes and about 50% were NPY secreting. Our tween the plasma and tumor tissue NPY concentrations reported by Corder et al. But in our study plasma and tissue IR-NPY concentrations in 13 patients with pheochromocytoma seemed continuously distributed and could not be clearly divided into 2 subtypes, and cases of pheochromocytoma with a normal plasma IR-NPY concentration were about 23%.
The present study also revealed the highest concentration of IR-NPY in plasma obtained from the drainage vein of a tumor in 2 patients with pheochromocytoma. The increase in IR-NPY in the peripheral plasma in these 2 patients was not so marked as in the other patients with pheochromocytoma in this study. Plasma IR-NPY in the drainage veins of tumors was about 100 pg/ml higher than in other veins. Intraand interassay coefficients of variation of this assay were about 10%, therefore this increase in the drainage vein could be significant and reflect the release of NPY from the tumors of pheochromocytoma patients.
Reverse phase HPLC revealed that most of the NPY immunoreactivity in plasma and tumor tissue extracts of pheochromocytomas was eluted in an identical position wtih synthetic human NPY. The antibody to NPY used in this study has 20.6% cross-reaction with PYY.
However, the results of HPLC indicate that NPY immunoreactivity in pheochromocytoma is NPY itself and not PYY. The results also suggest that in the extraction procedures most of the NPY does not change into NPY with oxidated methionine and only a small amount changes to that form.
NPY is known to have a potent vasoconstrictor action and potentiate a vasoconstrictor action of norepinephrine in vivo and in vitro (Lundberg et al., 1982; Ekblad et al., 1984; Wahlestedt et al., 1985; Itoi et al., 1986) . NPY has also a presynaptic inhibitory action on norepinephrine secretion (Allen et al., 1982; Lundberg et al., 1984) . In the present study we could not find the difference between the blood pressure or other clinical symptoms of the patients having pheochromocytoma with greatly increased plasma IR-NPY and those with normal or mildly increased plasma IR-NPY. Some cases of pheochromocytomas with normotension or hypotension were known. Two of 13 patients with pheochromocytoma in this study were normotensive. These 2 patients consulted our hospital because the presence of adrenal tumor had been revealed by computerized body tomography and by ultrasonography in local clinics, and did not show any hypertension in spite of increased plasma catecholamine without anti-hypertensive agents during the dmission period before surgery. However, plasma IR-NPY in these 2 cases was increased (454 and 1103 pg/ml, respectively). Further studies are needed to clarify the relationship between NPY and blood pressure and other clinical symptoms in patients with pheochromocytomas.
In conclusion, there is a significant corelation between plasma and tumor tissue IR-NPY concentrations in 13 cases of pheochromocytoma. The highest concentration of IR-NPY was found in plasma obtained from the drainage vein of a tumor in 2 cases of pheochromocytoma.
These findings indicate that the tumor release NPY into the systemic circulation in patients with pheochromocytoma.
